HTT and Huntington disease: These findings strongly indicate that CRISPR/CasRx-mediated RNA editing holds promise as a novel therapeutic strategy for HD, as it effectively reduces mHTT expression by targeting HTT mRNA and alleviates HD-associated neuropathology.